Duggirala Pallamraju—Vice-Chair, Commission C

2021 ◽  
Vol 212 ◽  
pp. 5-6
Keyword(s):  
Vice Chair

Message from the ISHRS 2018 Surgical Assistants Chair & Vice Chair

2018 ◽  
Vol 28 (4) ◽  
pp. 161-161
Author(s):  
Aileen Ullrich ◽  
Pawlak Deanne
Keyword(s):  
Vice Chair ◽  
Surgical Assistants

Message from the ISHRS 2018 Surgical Assistants Chair & Vice Chair

2018 ◽  
Vol 28 (2) ◽  
pp. 79-79
Author(s):  
Aileen Ullrich ◽  
Deanne Pawlak
Keyword(s):  
Vice Chair ◽  
Surgical Assistants

PIAPA introduces new Chair and Vice Chair

2019 ◽  
Vol 8 (6) ◽  
pp. 290-290
Author(s):  
Linda Mather ◽  
Bev Kelly
Keyword(s):  
New Members ◽  
Vice Chair

This month, PIAPA welcomes some new members to the organisation. Here, Linda Mather, PIAPA Chair and Bev Kelly, PIAPA Vice Chair, introduce themselves, and discuss their aspirations in their new roles with the organisation

scholarly journals 466 Use of a 27-gene immuno-oncology (IO) assay to associate response to single-agent immune checkpoint inhibitor (ICI) therapy in advanced-stage NSCLC patients from a large Canadian cohort

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A495-A495
Author(s):  
David Saltman ◽  
Nicole Croteau ◽  
Heather Lockyer ◽  
Rob Seitz ◽  
Frank McMahon ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lung Cancer ◽  
Retrospective Study ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Single Agent ◽  
Research Project ◽  
Vice Chair ◽  
Nsclc Patients

BackgroundLung cancer is the leading cause of cancer-related deaths worldwide. The advent of ICIs specifically targeting programmed cell death protein-1 (PD-1), or its ligand (PD-L1) represents a major therapeutic advance that is now included in standard of care regimens for non-small-cell-lung cancer (NSCLC). PD-L1 expression measured by immunohistochemistry (IHC) staining is the current gold standard predictive biomarker for immune checkpoint inhibitor (ICI) therapy in NSCLC, however many factors beyond PD-L1 expression alone affect the outcome of ICI therapy. Evaluation of other factors to better inform clinical practice will reduce both the potential for adverse immune-related toxicities and expenditure on ineffective costly therapies while potentially identifying patients otherwise missed by PD-L1 staining. The 27-gene IO assay is a RT-qPCR based gene expression panel1 that was developed to classify the tumor immune microenvironment (TIME). It has been shown to be associated with response to ICI therapy in multiple tumor types including triple negative breast cancer, metastatic urothelial carcinoma, and NSCLC where the association was independent of PD-L1 status in patients treated either with monotherapy or combination therapy.2 Currently, BC Cancer measures PD-L1 status by IHC using the PD-L1 22C3 PharmDx assay and reports the tumor proportional score (TPS) to inform clinical decision. Patients with a TPS ≥ 50% may be eligible for first-line treatment with ICI monotherapy and those with < 50% TPS are eligible for second line or later ICI monotherapy. We established this retrospective study of ICI monotherapy treated NSCLC patients to assess the 27-gene IO assay as an informative biomarker for NSCLC ICI treatment decisions.MethodsThis retrospective study is utilizing the BC Cancer Study Database to select approximately 150 patients with stage IIIB or IV NSCLC treated with single-agent ICI therapy across four BC Cancer centers from 2017 forward (figure 1). Patients are selected based on availability of adequate biopsy specimens (FFPE with at least 20% tumor content), availability of PD-L1 IHC results or sufficient tissue to conduct staining, and for whom outcome data is available via chart review. RNA from patient samples is isolated from FFPE biopsies (either primary or metastatic sites) and those that yield ≥50ng RNA will be analyzed by the 27-gene IO assay 1 to derive IO scores (IO positive or IO negative) based on previously defined thresholds.3 The association between patient outcomes on ICI monotherapy and IO scores and PD-L1 IHC will be reported and compared.Abstract 466 Figure 1Schematic representation of patient workflow forReferencesSaltman, A, et al. Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management? Ther Adv Urol 2021;13: 1756287221997186.Ranganath HJA, Smith JR, et al. One-year progression-free survival in lung cancer patients treated with immune checkpoint inhibitors is significantly associated with a novel immunomodulatory signature but not PD-L1 staining. in SITC. Journal Immunotherapy Cancer. 2019.Nielsen, TJ, et al. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon 2021;7(3):e06438.Ethics ApprovalThe University of British Columba BC Cancer Research Ethics Board Chair, Vice-Chair or second Vice-Chair, has reviewed the above described research project, including associated documentation, and finds the research project acceptable on ethical grounds for research involving human subjects. All participants have provided informed consent before taking part in the study. REB Number H20-02635.

scholarly journals Interview with Guido Rings: “We need intercultural solidarity if we want to survive and prosper in a world hit by ultranationalism”

2021 ◽  
Vol 2 (1) ◽  
pp. 75
Author(s):  
Stephen Trinder
Keyword(s):  
Prime Minister ◽  
The Other ◽  
Right Wing ◽  
David Cameron ◽  
Far Right ◽  
High Profile ◽  
Vice Chair ◽  
The Uk ◽  
Executive Agency ◽  
The Eu

As a master’s and Ph.D. student at Anglia Ruskin University in 2011, I recall the central message in lectures given by my eventual Ph.D. supervisor Professor Guido Rings was that we cannot underestimate the enduring strength of the legacy of colonialism in Europe and its influence on shaping contemporary attitudes towards immigration. Indeed, as I was completing my studies, I became increasingly aware of the negative rhetoric towards migrants in politics and right-wing press. In an attempt to placate the far-right of his party and address a growing threat from the UK Independence Party (UKIP), a discourse of ‘othernising’ migrants on the basis of their supposed rejection of ‘Britishness’ from former UK Prime Minister David Cameron in particular caught my attention. The result of this was tightening of immigration regulations, which culminated of course in the now-infamous Brexit vote of 2016. Almost a decade after my graduation, Professor Rings is currently Vice Chair for the Research Executive Agency of the European Commission and continues to work at Anglia Ruskin University at the level of Ph.D. supervisor. He still publishes widely in the field of Migration Studies and his recent high-profile book The Other in Contemporary Migrant Cinema (Routledge, 2016) and editorships in the fields of culture and identity (iMex Interdisciplinario Mexico) argue for increased intercultural solidarity in Europe as well as a strengthening of supranational organizations like the EU and the UN to offset growing nationalism. I got in touch with Professor Rings to find out where he feels Europe stands today with regard to migration and get his comments on the continued rise of nationalism on the continent.

scholarly journals The Activities and Responsibilities of the Vice Chair for Education in U.S. and Canadian Departments of Medicine

2012 ◽  
Vol 87 (8) ◽  
pp. 1041-1045 ◽  
Author(s):  
Erica Brownfield ◽  
Benjamin Clyburn ◽  
Sally Santen ◽  
Gustavo Heudebert ◽  
Paul A. Hemmer
Keyword(s):  
Vice Chair
Sign in / Sign up

Export Citation Format

Share Document